CAR T-cell studies at UCL derived from UCL technology
The UCL campus (inc. UCLH and GOSH) has Europe’s largest CAR T-cell programme. The campus has 10 studies using technology used at UCL. Many are academic, but several are funded by industrial partners.
| Name | NCT Link | Description | Funder/Sponsor | Status/Links |
|---|---|---|---|---|
| COBALT | NCT02431988 | Anti-CD19 CAR T-cell therapy for relapsed / refractory Diffuse Large B-cell Lymphoma. | Bloodwise / UCL | Completed |
| CARD | NCT02893189 | Haematopoietic stem cell transplant donor derived CAR T-cells for relapsed / refractory B-cell malignancy. One of the first studies to utilized automated CAR T-cell manufacture. | EU Framework 7 ATECT Consortium | Completed |
| CARPALLv1 | NCT02443831 | This study tests a new type of CD19 CAR (CAT-41BB-z) with a fast binding kinetic which is designed to reduce toxicity in paediatric and young adults with relapsed / refractory B-cell acute lymphoblastic leukemia (B-ALL). | Children With Cancer / UCL | Completed. Study shows excellent safety and engraftment profile of CAT-41BB-Z receptor. Study findings published: Ghorashian et al, Nat Med 2019 Sep;25(9):1408-1414 |
| ALLCAR19v1 | NCT02935257 | This is a sister study to CARPALL and tests CAT-41BB-Z in adults with relapsed / refractory B-ALL. | NIHR / UCL | Completed. Study confirms excellent safety and engraftment profile of CAT-41BB-Z in 20 patients. Study findings published: Roddie et al, JCO, doi: 10.1200/JCO.21.00917. Note: phase II registration study (Felix): NCT04404660. |
| UCART19 | NCT02808442 | This is the first test of gene-edited CAR T-cells. This study tests allogeneic ,off-the-shelf, CD19 CAR T-cells for relapsed B-ALL. See Qasim et al, Sci Transl Med. 2017 Jan 25;9(374). | Cellectis/Cellectis | Completed. Study published by Benjamin et al, Lancet, 2020 Dec 12;396(10277):1885-1894. |
| 1RG-CART | NCT02761915 | Autologous CAR T-cell targeting of GD2 for children with relapsed / refractory neuroblastoma. | CRUK/CRUK | Completed. This study showed anti-tumour activity and immune effects of GD2 CAR. Study findings published: Straathof et al, Sci Transl Med 2020 Nov 25;12(571). |
| AUTO-02 | NCT03287804 | Anti-BCMA/TACI CAR T-cell therapy for refractory multiple myeloma. See Lee et al, Blood. 2018 Feb 15;131(7):746-758. | AUTOLUS/AUTOLUS | Completed. |
| AUTO-03 AMELIA | NCT03289455 | This study tests a bi-cistronic CAR cassette which co-expresses a CD19 CAR and a CD22 CAR (AUTO-03) with the aim of preventing relapse due to down-regulation of CD19. AMELIA tests AUTO-03 in paediatric relapsed / refractory B-ALL. | AUTOLUS/AUTOLUS | Completed. |
| AUTO-03 ALEXANDER | NCT03287817 | ALEXANDER tests AUTO-03 in patients with relapsed / refractory DLBCL in combination with PD1 blockade. | AUTOLUS/AUTOLUS | Completed. |
| AUTO-04 | NCT03590574 | Tests a new way to target T-cell lymphomas by targeting one isoform of the T-cell receptor. See Maciocia et al, Nat Med. 2017 Dec;23(12):1416-1423. | AUTOLUS/AUTOLUS | Recruiting. |
| CAROUSEL | NCT04443829 | Tests CAT19 in Primary CNS Lymphoma. Both intravenous and intra-ventricular routes of administration are tested. | Wellcome Trust / UCL | Recruiting. |
CARPALLv2 (CAT/9A8) | NCT02443831 | This is a continuation of the CARPALL study. Since the main mode of relapse was CD19 negative escape, the product has been modified by co-transduction with a highly sensitive CD22 CAR (9A8-41BB-Z). | Autolus / UCL | Recruiting. |
ALLCAR19v2 (basket cohort) | NCT02935257 | This is a continuation of the ALLCAR19 study as a major amendment. The same therapeutic product is being tested in three additional cohors:
| Autolus / UCL | Recruiting An update was presented by Dr Roddie at EHA 2021, abstract #EP788 |
| MCARTY | NCT04795882 | Tests a high-sensitivity Fab BCMA CAR (D8Fab-41BB-Z) in patients with refractory Myeloma. An additional cohort of patients will receive T cells co-transduced with CAT-41BB-Z. CAR T cells will be manufactured in AKTiVIII. | AUTOLUS/UCL | Regulatory |
| KCAT19 | Q2 2021 | Tests a novel approach for generating allogeneic CAR T cells without genome editing | MRC/UCL | Scale-up |
| GLIOV3 | Q3 2021 | EGFRvIII CAR T cell therapy with | Moulton/UCL | Scale-up |
| DMGRA2 | Q3 2021 | Multi-modular IL13RA CAR T cell therapy for Diffuse Midline Glioma | Moulton & Abbie's Army/UCL | Pre-clinical |
| MCAR30 | Q4 2021 | Multi-edited CD30 CAR T cell therapy for refractory Hodgkin Disease | Moulton/UCL | Pre-clinical |
| MCARGD2 | Q4 2021 | Multi-modular GD2 CAR T cell therapy for relapsed / refractory Neuroblastoma | Autolus/UCL | Scale-up |
